Copyright
©The Author(s) 2025.
World J Gastrointest Oncol. Jun 15, 2025; 17(6): 104592
Published online Jun 15, 2025. doi: 10.4251/wjgo.v17.i6.104592
Published online Jun 15, 2025. doi: 10.4251/wjgo.v17.i6.104592
Table 1 Univariate analysis of factors associated with response to neoadjuvant chemotherapy for advanced gastric cancer, n (%)/mean ± SD
| Relevant factors | Effective group (n = 121) | Ineffective group (n = 64) | x2/t value | P value |
| Gender | 3.276 | 0.056 | ||
| Male | 80 (66.12) | 45 (70.31) | ||
| Female | 41 (33.88) | 19 (29.69) | ||
| Age (years) | 1.811 | 0.075 | ||
| ≤ 60 | 52 (42.98) | 26 (40.63) | ||
| > 60 | 69 (57.02) | 38 (59.37) | ||
| BMI (kg/m2) | 1.542 | 0.087 | ||
| ≤ 24 | 103 (85.12) | 53 (82.81) | ||
| > 24 | 18 (14.88) | 11 (17.19) | ||
| ECOG score (points) | 3.399 | 0.055 | ||
| 0 | 50 (41.32) | 27 (42.19) | ||
| 1 | 71 (58.68) | 37 (57.81) | ||
| Smoking history | 1.417 | 0.090 | ||
| Yes | 39 (32.23) | 26 (40.63) | ||
| No | 82 (67.77) | 38 (59.37) | ||
| Drinking history | 2.317 | 0.065 | ||
| Yes | 58 (47.93) | 35 (54.69) | ||
| No | 63 (52.07) | 29 (45.31) | ||
| Tumor site | 1.976 | 0.070 | ||
| Cardiogastric fundus | 39 (32.23) | 21 (32.81) | ||
| Gastric body | 17 (14.05) | 9 (14.06) | ||
| Antrum of the stomach | 59 (48.76) | 26 (40.63) | ||
| Whole stomach | 6 (4.96) | 8 (12.50) | ||
| Tumor diameter (cm) | 7.435 | 0.016 | ||
| ≤ 5 | 76 (62.81) | 27 (42.19) | ||
| > 5 | 45 (37.19) | 37 (57.81) | ||
| Histological type | 6.632 | 0.024 | ||
| Tubular adenocarcinoma | 99 (81.82) | 40 (62.50) | ||
| Poorly differentiated adenocarcinoma | 10 (8.26) | 12 (18.75) | ||
| Heron cell carcinoma | 6 (4.96) | 9 (26.47) | ||
| Mixed type | 6 (4.96) | 3 (8.83) | ||
| Degree of differentiation | 1.605 | 0.084 | ||
| High differentiated | 5 (4.13) | 1 (1.56) | ||
| Moderate differentiation | 36 (29.75) | 14 (21.88) | ||
| Poorly differentiated/undifferentiated | 80 (66.12) | 49 (76.56) | ||
| Lymph node metastasis | 8.427 | 0.007 | ||
| No | 57 (47.11) | 19 (29.69) | ||
| Yes | 64 (52.89) | 45 (70.31) | ||
| Severe adverse reactions | 1.843 | 0.072 | ||
| Yes | 11 (9.09) | 10 (15.63) | ||
| No | 110 (90.91) | 54 (84.37) | ||
| Chemotherapy cycle (cycles) | 4.856 | 0.041 | ||
| ≤ 3 | 83 (68.60) | 55 (85.94) | ||
| > 3 | 38 (31.40) | 9 (14.06) | ||
| Hematocrit (%) | 4.784 | 0.042 | ||
| < 33 | 42 (34.71) | 33 (51.54) | ||
| ≥ 33 | 79 (65.29) | 31 (48.44) | ||
| Mean corpuscular hemoglobin content (%) | 55.27 ± 5.12 | 42.60 ± 4.83 | 2.678 | 0.009 |
| Erythrocyte protein concentration (%) | 15.23 ± 1.36 | 13.85 ± 2.06 | 2.292 | 0.036 |
| Red blood cell distribution width | 57.79 ± 2.74 | 45.56 ± 3.04 | 2.557 | 0.015 |
| Hemoglobin (g/L) | 7.996 | 0.010 | ||
| < 107 | 57 (47.11) | 45 (70.31) | ||
| ≥ 107 | 64 (52.89) | 19 (29.69) | ||
| Platelets (× 109/L) | 5.785 | 0.033 | ||
| > 266 | 62 (51.24) | 51 (79.69) | ||
| ≤ 266 | 59 (48.76) | 13 (20.31) |
- Citation: Qiu TH, Wen HY, Huang YL. Significance of hemoglobin and hematocrit changes in predicting patient survival and efficacy of neoadjuvant chemotherapy for advanced gastric cancer. World J Gastrointest Oncol 2025; 17(6): 104592
- URL: https://www.wjgnet.com/1948-5204/full/v17/i6/104592.htm
- DOI: https://dx.doi.org/10.4251/wjgo.v17.i6.104592